Kiestra IdentifA system is developed for the automation of the preparation of microbiology bacterial identification testing
Becton, Dickinson and Company (BD) has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its Kiestra IdentifA system.
The company has developed the Kiestra IdentifA system for the automation of the preparation of microbiology bacterial identification testing.
BD Kiestra IdentifA is claimed to be the only FDA-cleared solution available under a track-connected system for lab automation to support specimen preparation workflows for regular and challenging isolate types.
The system allows the lab technician to use BD Synapsys Informatics for the selection of discrete bacterial colonies from a digital plate image.
Later, robotics will pick the selected organisms and prepare the sample for specific identification testing.
By automating manual steps, the system is expected to minimise the human error when preparing samples for bacterial identification and produce more precise diagnoses for patients.
BD integrated diagnostic solutions president Brooke Story said: “BD continues to invest in automation and innovation for the microbiology laboratory to enable smart, connected, end-to-end workflows designed to accelerate insights and efficiency.
“Our ‘discovery to diagnostics’ strategy positions us to provide best-in-class solutions at every point along this continuum.”
According to the company, the integration of the BD Synapsys Informatics solution with the BD Kiestra IdentifA, in combination with matrix-assisted laser desorption/ionisation-time of flight (MALDI-ToF) mass spectrometry, will be able to deliver rapid and precise identification of bacteria and yeasts for enhanced clinician treatment decisions.
BD Synapsys Informatics solution is developed to enable labs to analyse their performance with enhanced microbiology informatics through a single, advanced platform with an intuitive, personalised user interface.